FDA Fast Track Designation for BI-1808 for the Treatment of Ovarian Cancer

“Receiving FDA Fast Track Designation for BI-1808 in ovarian cancer is an important milestone that reflects the significant unmet medical need in this difficult-to-treat disease and the strength of the clinical signals we have generated to date,” said Martin Welschof, Chief Executive Officer of BioInvent. “The data we have presented across both high-grade serous and clear cell subtypes underscore the potential of targeting TNFR2 to meaningfully enhance the activity of PD-1 inhibitors in tumors where these agents have historically shown limited benefit. This designation validates our development strategy and strengthens our commitment to advancing BI-1808 as a new treatment option for patients with ovarian cancer.”

Share:

More News

Taiho Oncology, Inc. completed a New Drug Application (NDA) submission to the U.S. Food and Drug Administration (FDA) for zipalertinib in combination with platinum-based chemotherapy for the treatment of patients with previously untreated, locally advanced or metastatic non-small cell lung cancer (NSCLC) harboring epidermal growth factor receptor (EGFR) exon 20

“This collaboration reflects our conviction that atebimetinib has the potential to become an essential backbone therapy in a broad range of combinations across MAPK-driven cancers,” said Ben Zeskind, Immuneering CEO and co-founder. “Atebimetinib’s unique tolerability profile and broad activity make it well suited to combine with a wide range of

“These final updated results provide continued evidence of the potential for γδ T cell therapies to drive activity and improve outcomes for patients,” said William Ho, CEO and co-founder of IN8bio. “The clinical outcomes and observed activity are supported by our correlative analysis, including histopathology, demonstrating the expansion and persistence

“Patients with RAS-mutated mCRC have no first-line therapies specifically approved for their disease, and Fast Track designation reflects the potential of onvansertib to address this serious unmet need,” said Mani Mohindru, PhD, President and Chief Executive Officer of Cardiff Oncology. “Our randomized Phase 2 data give us confidence that onvansertib